This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosenblatt, K. A. Articles by Stanford, J. L. Search for Related Content PubMed PubMed Citation Articles by Rosenblatt, K. A. Articles by Stanford, J. L.

Serologic Evidence of Human Papillomavirus 16 and 18 Infections and Risk of Prostate Cancer¹

Department of Community Health, University of Illinois at Urbana-Champaign, Champaign, Illinois 61820 [K. A. R.], and Program in Cancer Biology, Division of Human Biology [J. J. C., D. A. G.] and Program in Epidemiology, Division of Public Health Sciences [L. M. I., J. L. S.], Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024

Human papillomavirus (HPV) subtypes 16 and 18 are sexually transmitted and have been associated with an increased incidence of several anogenital tumors. Although previous epidemiological studies have suggested that sexual behaviors such as an early age at first intercourse and larger numbers of sexual partners are also related to an increased risk of prostate cancer, seroepidemiological studies of these infectious agents in relation to prostate cancer have produced differing results. To further evaluate this potential relationship, we completed a population-based control study in King County, Washington. Middle-aged (40–64 years) men diagnosed with prostate cancer (n = 642) were ascertained through the Seattle-Puget Sound Surveillance, Epidemiology, and End Results cancer registry between January 1993 and December 1996. Controls (n = 570) of similar age were selected from the same population as the cases by random digit dialing. Overall, there was no association between serological evidence of prior HPV-16 (adjusted odds ratio, 1.06; 95% confidence interval, 0.71–1.57) or HPV-18 (adjusted odds ratio, 1.36; 95% confidence interval, 0.69–2.69) infection and the risk of prostate cancer. Analyses of clinical features demonstrated no relationship between HPV infection status and Gleason score, stage of disease, or a combined measure of disease aggressiveness. Our findings indicate that HPV-16 and HPV-18 are not associated with prostate cancer risk.

This article has been cited by other articles:

				S. Sutcliffe, E. Giovannucci, C. A. Gaydos, R. P. Viscidi, F. J. Jenkins, J. M. Zenilman, L. P. Jacobson, A. M. De Marzo, W. C. Willett, and E. A. Platz Plasma Antibodies against Chlamydia trachomatis, Human Papillomavirus, and Human Herpesvirus Type 8 in Relation to Prostate Cancer: A Prospective Study Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1573 - 1580. [Abstract] [Full Text] [PDF]

				Z. Korodi, J. Dillner, E. Jellum, S. Lumme, G. Hallmans, S. Thoresen, T. Hakulinen, P. Stattin, T. Luostarinen, M. Lehtinen, et al. Human Papillomavirus 16, 18, and 33 Infections and Risk of Prostate Cancer: A Nordic Nested Case-Control Study Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2952 - 2955. [Abstract] [Full Text] [PDF]

				G. S. Palapattu, S. Sutcliffe, P. J. Bastian, E. A. Platz, A. M. De Marzo, W. B. Isaacs, and W. G. Nelson Prostate carcinogenesis and inflammation: emerging insights Carcinogenesis, July 1, 2005; 26(7): 1170 - 1181. [Abstract] [Full Text] [PDF]

				L. Fernandez, Y. Galan, R. Jimenez, A. Gutierrez, M. Guerra, C. Pereda, C. Alonso, E. Riboli, A. Agudo, and C. Gonzalez Sexual behaviour, history of sexually transmitted diseases, and the risk of prostate cancer: a case-control study in Cuba Int. J. Epidemiol., February 1, 2005; 34(1): 193 - 197. [Abstract] [Full Text] [PDF]